Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial
Clearmind Medicine reported positive safety findings from Part A of its Phase I/II trial for CMND-100, with all 24 participants successfully completing treatment across four dose cohorts. The study achieved its primary endpoint of safety and tolerability, showing no serious adverse events even at the highest evaluated dose of 160 mg.
Key figures
- Drug Name
- CMND-100
- Phase Of Trial
- Phase I/II
- Max dose mg
- 160
- Participants
- 24
- Granted patents
- 32
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.